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Abstract. A total synthesis of 2-amino-7-(O-D-ribofuranosyl)pyrrolo[2,3-dlpyrimidin-4-one- 
5-carboxylic acid has been accomplished and confirms the previous structural assignment for the 
nucleoside antibiotic cadeguomycin. 
The isolation, characterization, and chemical synthesis 
2-4 
of the 
pyrrolo[2,3_d]pyrimidine nucleoside antibiotics tubercidin, toyocamycin, and sangivamycin, as 
well as their biological and chemotherapeutic activity, 
2-5 
created considerable interest in 
the synthesis of compounds related to this class of adenosine analogs. The isolation and 




from certain t-RNA's prompted considerable 
interest in the synthesis as well as studies on the biological and chemotherapeutic activity of 
various guanosine- like pyrrolo[2,3_dlpyrimidine nucleosides. 
8-11 
Interest in the area of - 
ouanosine-like pyrrolo[2,3_dlpyrimidine nucleosides has been renewed by a recent report on the - 
isolation and characterization of the new and novel nucleoside antibiotic cadeguomycin 
12,13 
as 2-amino-7-(B-D-ribofuranosyl)pyrrolo[2,3-~lpyrimidin-4-one-5-carboxylic acid (2,. This 
antibiotic was reported 
13 
to have inhibitory effects on transplantable animal tumors but no 
significant antimicrobial activity against bacteria and fungi. It has been assumed 
12 
that 
this nucleoside antibiotic possessed the structure 5 solely on the basis of physicochemical - 
properties. We now wish to report a total synthesis of the nucleoside 2-amino-7-(B-D-ribo- 
furanosyl)pyrrolo[2,3-dlpyrimidin-4-one-5-carboxylic acid (2, cadeguomycin). 
We initiated two separate routes for the total synthesis of cadeguomycin, with each route 
being designed to ultimately afford the desired antibiotic. In the first route investigated, 
we envisaged the use of 2-amino-7-(O-D-ribofuranosyl)pyrrolo[2,3-dl-pyrimidin-4-one-5- - 
carboxamide (4) as the immediate precursor of cadeguomycin. The synthesis of this precursor 
(4-j was accomplished from the nucleoside antibiotic toyocamycin via a seven step sequence. - 
However, the low yield (14%) from the last step, treatment of 2-amino-5-cyano-7-(&D- 
ribofuranosyl)pyrrolo[2,3-dl-pyrimidin-l-one 
8 
- (2) in concentrated ammonium hydroxide with 
hydrogen peroxide at < 20°, prompted us to investigate an alternate synthesis of 4. A - 
successful alternative synthesis of 4 involved the conversion of 2-chloro-7-(B-D-ribo- - 
furanosyl)pyrrolo[2,3-d]pyrimidin-4-one-5-carboxamide l4 CL,, with liquid ammonia in a sealed 
steel reaction vessel (lOO", 96 hrs), into 4 in 86% yield, 
16 
mp 260.5-261.S" - (dec., 
01 
browning began > 228 ; H-NMR(6OMHz, DMSO-s): 10.95 (br s, lH, N3-H). 7.55 (s, lH, 
Cs-E), 9.54 and 7.10 (two br s, ZH, CONE2), 6.50 (br s, ZH, NE2) 5.90 (d, lH, Cl,-HI 
Jl',Z' 
= 6.4 Hz). The nucleoside 4 (15 mg) was then treated with 3N HCl at 80° for 44 
hrs. The pH of the solution was adjusted to pH 8 by the addition of dilute ammonium hydroxide 
4793 
4194 
solution. The water was removed by lyophilisation and the resulting white solid was isolated by 
HPLC (Whatman Partisil ODS-3,0-20% MeOH/H20 gradient, retention time 53 min.) in 7% yield. It 
was determined that this solid was identical to cadeguomycin (2) (See Table I). However, the 
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reported in reference 12 may be due to the difference in the 











A solution of the nucleoside 3 (50 mg 0.163 mm01) in 3.5 mL of 6N sodium hydroxide was - - 
heated at reflux for 3 hrs. Ethanol (40 mL) was added to the chilled reaction mixture (ice 
bath) which effected a precipitation of the sodium salt of 1. Decantation of the reaction 
4795 
mixture furnished a thick syrup-like residue which was triturated with 40 mL of cold ethanol. 
The remaining solid was dissolved in water and the pH of the solution was adjusted to pH 4.0 
using an ion-exchange resin (Amberlite, IR-120, H+-form). A suspension of the nucleoside 5 
was decanted from the resin, the resin was washed with cold water (2x10 a&) and the liquid 
removed by lyophilisation. The resulting white solid (30 mg) was extracted with 20 and then 10 
mL of hot methanol. The methanol extracts were evaporated to dryness in vacua to yield 19.4 mg -- 
(36.5%) of 2, which was dried over P 0 2 5 at 800/0.1 mm Hg for 15 hrs; mp 305-308O (dec., 
browning began > 2400). A sample was recrystallized from a methanol:water(7:l/v:v) mixture 
and then dried under the same conditions as described above: mp 327-330° (dec., brewing 
began > 2600). 'H-NMR(360 MHz, DMSO-s): 14.52 (6, lH, CGCH); 11.62 (br s, lH, N3-E); - 
7.83 (s, lH, C6-s); 6.79 (br s, 2H, NIi2); 5.90 (d, lH, Cl,+, Jl, 2, = 6.2 Hz); Ir (KBr, 
cm-l): 3350, 3440 (OH, NH); 1650 (CGOH) and essentially identical tb the fingerprint region 
previously reported 
12 
for cadeguomycin. The CIMS (CH4) of the hexasilylated 
15 
nucleoside 
5 showed M and M-15 ions (758 and 743 m/s, respectively) which supported our structural - 
assignment for the nucleoside 5. Characteristic peaks 
15 
of the base series calculated for - 
this structure were observed in GC EIMS (70 e.v.): B+188; B+131; B+128; B+116; B+lOO; B+74; 
B+58: B+30; Bfl3; B+2; B+l; B(409 m/z); B-14; and peaks related to the sugar moiety were 
15 
identical to those previously reported ; a peak for the molecular ion was not obtained under 
these conditions (EIMS). 
The physicochemical data obtained for the nucleoside 5 proved to be very different from - 
either the nucleoside 3 or the nucleoside 4, but essentially identical to the data reported 
12 
- 
for the naturally occurring cadeguomycin (Table 1). Therefore, this unequivocal synthesis of 
the nucleoside 2 and the comparison of physiochemical data for 5 and the reported values for - 
cadeguomycin corroborates the previous structural assignment of cadeguomycin as 
2-amino-7-(S-D-ribofuranosyl)pyrrolo[2,3-dlpyrimidin- 4-one-5-carboxylic acid. 
The synthetic pathway we have developed, vide supra, for the total synthesis of the -- 
nucleoside antibiotic cadeguomycin can now be used to obtain a number of specific analogs of 
cadeguomycin for more extensive biological and chemotherapeutic evaluations. 
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